Lexaria Bioscience (LEXX) Non-Current Debt (2011 - 2020)

Lexaria Bioscience (LEXX) posted Non-Current Debt of $30852.0 for Q4 2020, up 0.59% sequentially from $30670.0 in Q3 2020.

Lexaria Bioscience (LEXX) Non-Current Debt (2011 - 2020) Analysis & Trends

Lexaria Bioscience has reported Non-Current Debt for 2 years, with the latest figure at $30852.0 in Q4 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $30852.0 in Q4 2020, while the trailing twelve-month figure through Nov 2020 was $30852.0 (changed N/A YoY) and the FY2020 annual result came in at $30670.0, changed N/A from the prior year.
Non-Current Debt advanced to $30852.0 in Q4 2020 per LEXX's latest filing, from $30670.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $30852.0 in Q4 2020 and troughed at $28756.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.98 Bn	77.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.11 Bn	59.92 Bn	1.37 Bn	-
4	Moderna	55.73 Bn	50.59 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn	-
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	8.96 Bn
10	Lexaria Bioscience	10.14 Mn	6.52 Mn	-	-

Download Data